| Business Summary | | Bentley
Pharmaceuticals,
Inc.
is
a
drug
delivery
company
specializing
in
the
development
of
products
based
on
proprietary
drug
delivery
systems.
The
Company
also
has
a
commercial
presence
in
Europe,
where
it
manufactures,
markets
and
distributes
branded
and
generic
pharmaceutical
products.
The
Company
owns
rights
to
certain
United
States
and
international
patents
and
related
technology
covering
methods
to
enhance
the
absorption
of
drugs
delivered
to
biological
tissues.
In
Spain,
the
Company
acquires,
licenses
or
develops
and
registers
late
stage
products,
and
manufactures,
packages
and
distributes
its
own
products
and
products
under
contract
for
other
pharmaceutical
companies.
During
2000,
99%
of
the
Company's
revenues
were
derived
from
its
operating
subsidiaries,
Laboratorios
Belmac
S.A.
and
Laboratorios
Davur
S.L.,
in
Spain. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Bentley
Pharmaceuticals,
Inc.
is
engaged
in
the
manufacturing,
marketing
and
distribution
of
pharmaceutical
products
in
Spain,
with
limited
product
distribution
in
the
US.
For
the
six
months
ended
6/30/01,
sales
rose
23%
to
$11.9
million.
Net
income
totalled
$2.1
million
vs.
a
loss
of
$141
thousand.
Revenues
reflect
an
increase
in
sales
in
the
Spanish
generic
drug
market.
Earnings
reflect
the
inclusion
of
a
$5
million
gain
on
the
sale
of
a
drug
license. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| James Murphy, 51 Chairman,
Pres and CEO | $559K | -- | Michael McGovern, 57 Vice
Chairman | -- | -- | Robert Stote, M.D., 61 Sr.
VP, CSO | 120K | -- | Michael Price, 43 VP,
CFO, Sec., Treasurer | 229K | -- | Robert Gyurik, 54 VP
of Pharmaceutical Devel. | 179K | $4.3K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|